UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 240

Sortiert nach

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Link zum Volltext

Verfügbarkeit prüfen

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Annals of oncology, 2017-11, Vol.28 (11), p.2768-2772

2017

Link zum Volltext

Verfügbarkeit prüfen

ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial

Geburtshilfe und Frauenheilkunde, 2015-09, Vol.75 (9), p.935-940

2015

Link zum Volltext

Verfügbarkeit prüfen

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Breast cancer research and treatment, 2019-06, Vol.175 (2), p.389-399

2019

Link zum Volltext

Verfügbarkeit prüfen

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial

Gynecologic oncology, 2017-08, Vol.146 (2), p.279-284

2017

Link zum Volltext

Verfügbarkeit prüfen

Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET)

Annals of oncology, 2018-10, Vol.29, p.viii106-viii106

2018

Link zum Volltext

Verfügbarkeit prüfen

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

Annals of oncology, 2004-03, Vol.15 (3), p.440-449

2004

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Annals of oncology, 2018-10, Vol.29, p.viii703-viii703

2018

Link zum Volltext

Verfügbarkeit prüfen

Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer

Journal of cancer research and clinical oncology, 2013-11, Vol.139 (11), p.1909-1916

2013

Link zum Volltext

Verfügbarkeit prüfen

Dermatologische Nebenwirkungen der Zytostatika

Aktuelle Dermatologie, 2015-03, Vol.41 (3), p.104-109

2015

Link zum Volltext

Verfügbarkeit prüfen

CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary

Journal of cancer research and clinical oncology, 2013-04, Vol.139 (4), p.551-556

2013

Link zum Volltext

Verfügbarkeit prüfen

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

Breast (Edinburgh), 2019-06, Vol.45, p.22-28

2019

Link zum Volltext

Verfügbarkeit prüfen

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Annals of oncology, 2019-05, Vol.30, p.iii67-iii67

2019

Link zum Volltext

Verfügbarkeit prüfen

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

European journal of cancer (1990), 2018-11, Vol.104, p.160-168

2018

Link zum Volltext

Verfügbarkeit prüfen

Thyroid disorders during pregnancy--important for the mother and the fetus

Deutsche medizinische Wochenschrift (1946), 2009-01, Vol.134 (3), p.87

Grischke, E-M

2009

Link zum Volltext

Verfügbarkeit prüfen

169 PazoDoble – Pazopanib vs. Pazopanib plus Gemcitabine in relapsed or metastatic uterine leiomyosarcomas or uterine carcinosacomas

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A153-A154

2021

Link zum Volltext

Verfügbarkeit prüfen

Electrochemotherapy for breast cancer - results from the INSPECT database

Annals of oncology, 2016-10, Vol.27, p.vi86-vi86

2016

Link zum Volltext

Verfügbarkeit prüfen

CNS metastases in breast cancer patients: prognostic implications of tumor subtype

Medical oncology (Northwood, London, England), 2015, Vol.32 (1), p.400-400, Article 400

2015

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita

Annals of oncology, 2016-10, Vol.27, p.vi85-vi85

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 240

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(221)
Mit Volltextzugriff
(203)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(78)
Female
(73)
Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Adult
(42)
Pregnancy
(30)
Oncology
(27)
Middle Aged
(25)
Aged
(20)
Breast Cancer
(19)
Obstetrics & Gynecology
(17)
Prognosis
(17)
Infant, Newborn
(15)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Risk Factors
(12)
Breast Neoplasms - Pathology
(11)
Prospective Studies
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Follow-Up Studies
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019)

ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET)

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288]

Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer

Dermatologische Nebenwirkungen der Zytostatika

CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

Thyroid disorders during pregnancy--important for the mother and the fetus

169 PazoDoble – Pazopanib vs. Pazopanib plus Gemcitabine in relapsed or metastatic uterine leiomyosarcomas or uterine carcinosacomas

Electrochemotherapy for breast cancer - results from the INSPECT database

CNS metastases in breast cancer patients: prognostic implications of tumor subtype

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Suchergebnisse filtern